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Introduction
Monocyte/macrophage desensitization is characteristic for late-
phase immune responses (Liew et al., 2005). Confi  ned pro-
infl   ammatory cytokine expression and mediator synthesis is 
important to avoid pathological settings, such as sepsis or 
atherosclerosis (Hotchkiss and Karl, 2003; Hansson, 2005). 
Down-regulating proinfl  ammatory cytokine expression (TNF-α, 
interleukin [IL]-1β, and IFNγ) or proinfl  ammatory mediator 
release (nitric oxide and reactive oxygen species [ROS]) con-
comitantly switches the proinfl  ammatory phenotype toward an 
antiinfl  ammatory one. The latter is characterized by the synthe-
sis of antiinfl  ammatory cytokines, such as TGF-β or IL-10, and 
is often accompanied by cellular desensitization upon secondary 
proinfl  ammatory stimulation (Docke et al., 1997; Kalechman 
et al., 2002). Therefore, the identifi  cation of molecular mecha-
nisms contributing to cellular desensitization attracted growing 
interest (Docke et al., 1997; von Knethen and Brune, 2002).
One factor attenuating proinfl  ammatory gene expression 
is peroxisome proliferator–activated receptor (PPARγ). PPARγ 
is a nuclear hormone receptor that, upon agonist binding, trans-
activates gene expression as a heterodimer bound to retinoic 
acid receptor-α (Abdelrahman et al., 2005). Its role in blocking 
proinfl  ammatory gene expression comprises several options, 
mainly antagonizing signaling cascades. Specifi  cally, PPARγ 
negatively regulates transcription factors by scavenging tran-
scriptional coactivators, such as the cAMP-response element–
binding protein or the steroid receptor coactivator-1 (Yang et al., 
2000). However, a direct association with the transcription fac-
tors NF-κB, NF of activated T cells, signal transducer, and acti-
vator of transcription or NF-E2–related factor 2 (Ikeda et al., 
2000; Wang et al., 2001, 2004; Chung et al., 2003) blocks their 
recruitment to responsive elements in promoter structures of 
target genes. Recently, it has been shown that PPARγ is targeted 
to nuclear receptor corepressor–histone deacetylase-3 com-
plexes in response to ligand-dependent SUMOylation (Pascual 
et al., 2005), protecting these complexes from proteosomal de-
gradation. Normally, histone deacetylase-3 removes a corepres-
sor complex, provoking expression of proinfl  ammatory genes. 
Additionally, PPARγ represses activation of a mitogen-activated 
protein kinase, which keeps downstream transcription factors 
PPARγ1 attenuates cytosol to membrane 
translocation of PKCα to desensitize 
monocytes/macrophages
Andreas von Knethen, Mathias Soller, Nico Tzieply, Andreas Weigert, Axel M. Johann, Carla Jennewein, 
Roman Köhl, and Bernhard Brüne
Institute of Biochemistry I, Faculty of Medicine, Johann Wolfgang Goethe University, 60590 Frankfurt, Theodor-Stern-Kai 7, Germany
  R
ecently, we provided evidence that PKCα depletion 
in monocytes/macrophages contributes to cellular 
desensitization during sepsis. We demonstrate that 
peroxisome proliferator–activated receptor γ (PPARγ) ag-
onists dose dependently block PKCα depletion in response 
to the diacylglycerol homologue PMA in RAW 264.7 and 
human monocyte–derived macrophages. In these cells, we 
observed PPARγ-dependent inhibition of nuclear factor-κB 
(NF-κB) activation and TNF-α expression in response to 
PMA. Elucidating the underlying mechanism, we found 
PPARγ1 expression not only in the nucleus but also in 
the cytoplasm. Activation of PPARγ1 wild type, but 
not an agonist-binding mutant of PPARγ1, attenuated 
PMA-mediated PKCα cytosol to membrane translocation. 
Coimmunoprecipitation assays pointed to a protein–protein 
interaction of PKCα and PPARγ1, which was further 
substantiated using a mammalian two-hybrid system. Ap-
plying PPARγ1 mutation and deletion constructs, we iden-
tiﬁ  ed the hinge helix 1 domain of PPARγ1 that is responsible 
for PKCα binding. Therefore, we conclude that PPARγ1-
dependent inhibition of PKCα translocation implies a new 
model of macrophage desensitization.
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unphosphorylated and, consequently, inactive (Desreumaux 
et al., 2001). Moreover, PPARγ infl  uences the cell cycle by up- 
regulating p21 expression, which is an established cell cycle 
inhibitor (Han et al., 2004), or down-regulating phosphatase 
PPA2, which is known to adjust E2F/DP DNA-binding activity, 
which is necessary for the G1 to S-phase transition (Altiok et al., 
1997). In response to proinfl  ammatory stimulation, PPARγ-
  dependent gene transcription also contributes to cellular desen-
sitization. PPARγ agonists inhibit diacylglycerol (DAG)–PKC 
signaling by inducing DAG kinase-α (DGKα) expression (Verrier 
et al., 2004). This enzyme lowers the amount of DAG, which is 
an established PKC activator. Normally, DAG is released from 
membrane lipids and activates classical PKCs (Liu and Heckman, 
1998). Based on gene induction of DGKα as the underlying 
mechanism, this type of desensitization demands at least 6–15 h. 
Thus, it appears that PPARγ transrepresses proinfl  ammatory 
gene expression, often in a DNA-unbound state, by provoking 
direct protein–protein interactions.
We provide evidence for a new PPARγ-dependent mecha-
nism in blocking PKCα signaling. Depletion of PKCα is atten-
uated by PPARγ1 activation in RAW 264.7 cells or human 
primary monocyte–derived macrophages. Cytosolic localiza-
tion of PPARγ1 interferes with PKCα cytosol to membrane 
translocation, which is a prerequisite for its activation-dependent 
depletion. Translocation is restored in cells transfected with a 
dominant-negative PPARγ1 mutant. Coimmunoprecipitation 
studies and a mammalian two-hybrid system revealed a 
direct PPARγ1–PKCα interaction as the underlying mecha-
nism. PPARγ1 deletion constructs support the idea that ligand-
dependent PPARγ activation is necessary for PKCα binding, 
which is mediated by the helix 1 of the PPARγ1 hinge domain. 
Our data suggest a new mechanism for how activation of 
PPARγ1 blocks PKCα translocation, thereby achieving 
cellular desensitization.
Results
PPAR𝗄 agonists inhibit PKC𝗂 depletion
Recent data demonstrate that monocyte/macrophage desensiti-
zation in response to phagocytosis of apoptotic cells is achieved 
by attenuating PKCα signaling, which blocks NADPH oxidase–
dependent formation of ROS (Johann et al., 2006). There-
fore, we were interested in identifying molecular mechanisms 
interfering with PKCα depletion. A potential candidate known 
to affect the pro- versus antiinfl  ammatory phenotype in mono-
cytes/macrophages is PPARγ. Because controversial data exist 
concerning its expression in monocytic and macrophage cell 
lines, as well as in primary human monocytes and macrophages, 
we performed a fi  rst set of experiments determining PPARγ 
  expression in the monocytic cell lines and primary cells under 
investigation. As shown in Fig. 1 A, PPARγ is constitutively 
expressed in murine RAW 264.7 macrophages. In contrast, in 
THP-1 cells, PPARγ is only fractionally expressed, but differ-
entiation toward macrophages with 100 nM PMA for 24 h pro-
voked up-regulation of PPARγ (Fig. 1 A, lane 2 vs. 3). A similar 
expression pattern is observed in primary monocytes and macro-
phages, respectively. PPARγ is only marginally expressed in 
monocytes, but induced upon differentiation toward macrophages 
(Fig. 1 B). To identify the expressed PPARγ isoform 1 or 2, we 
performed a Western blot using human PPARγ1-transfected 
human embryonic kidney (HEK) cells as a positive control. Taking 
into consideration that murine and human PPARγ1 are identical 
in size (475 aa), we conclude that PPARγ1 is expressed in RAW 
264.7 macrophages, differentiated THP-1 cells, and primary 
macrophages (unpublished data). Based on these results, we choose 
RAW 264.7 cells, differentiated human THP-1 cells, and primary 
monocyte–derived macrophages as experimental cell models.
To analyze the role of PPARγ in macrophages in affecting 
PKCα activation, we pretreated RAW 264.7 macrophages for 
1 h with the PPARγ agonists ciglitazone and rosiglitazone, fol-
lowed by the addition of 100 nM PMA, which is a DAG homo-
logue and established activator of PKCα. As expected, PKCα 
depletion was observed in control cells in response to 100 nM 
PMA (Fig. 2 A, lane 2). Depletion of PKCα was attenuated in 
cells prestimulated with a PPARγ agonist, such as ciglitazone 
(Fig. 2 A, lanes 3 and 4) or rosiglitazone (Fig. 2 A, lanes 5 and 6), 
in a concentration-dependent manner. However, 1 μM PMA-
mediated PKCα depletion was not blocked (unpublished data). 
From these data, we conclude that PPARγ agonists attenuate 
activation-dependent PKCα depletion, in part controlled by the 
magnitude of the PKCα–activating stimulus. In PPARγ1 acti-
vating function (AF) 2 mutant overexpressing RAW 264.7 
macrophages (Johann et al., 2006), pretreatment with 10 μM 
rosiglitazone or 10 μM ciglitazone did not inhibit PKCα deple-
tion in response to PMA (Fig. 2 B).
Because a 1-h prestimulation period is short for gene ex-
pression and protein synthesis, we hypothesized that preserved 
PKCα expression did not require protein synthesis. To prove 
this assumption, we added the established translation inhibitor 
cyclohexamide (CHX) 1 h before PPARγ agonist stimulation 
Figure 1.  PPAR𝗄 expression in monocytes/macrophages. (A) PPARγ ex-
pression was determined in lysates of RAW 264.7 macrophages and in 
control versus differentiated THP-1 cells. For differentiation, cells were 
treated for 24 h with 100 nM PMA. Western blot was performed as 
described in Materials and methods. (B) PPARγ expression was analyzed 
by Western analysis in primary human monocytes and macrophages, dif-
ferentiated for 7 d with medium containing serum of AB-positive donors. 
Experiments were performed at least three times, and representative data 
are shown.PPARγ1 INHIBITS PKCα TRANSLOCATION • VON KNETHEN ET AL. 683
(Fig. 2 C). As expected, blocking translation with CHX did 
not interfere with the ability of PPARγ agonists to block 
PKCα depletion, suggesting a translation-independent mode 
of action.
The physiological signifi  cance of these results obtained in 
murine RAW 264.7 macrophages was verifi   ed in primary 
human monocyte–derived macrophages isolated from peripheral 
blood. Similar to RAW 264.7 cells, in primary macrophages, 
pretreatment with ciglitazone and rosiglitazone preserved 
PKCα expression upon PMA addition (Fig. 2 D).
Antiinﬂ  ammatory consequences 
of PPAR𝗄1–PKC𝗂 interaction
To elucidate whether the PPARγ1–PKCα interaction shows an 
impact on PKCα signaling in infl  ammatory gene expression in 
macrophages, we analyzed two proinfl  ammatory markers of 
macrophage activation, i.e., NF-κB DNA binding and TNF-α 
expression in response to PMA in RAW 264.7 macrophages. To 
determine activation of the proinfl  ammatory transcription factor 
NF-κB, we performed a set of electrophoretic mobility shift as-
says (EMSAs), demonstrating the DNA-binding capability of 
the transcription factor. As shown in Fig. 3 A, 100 nM PMA 
supplied for 3 h signifi  cantly induced NF-κB activation (Fig. 
3 A, second lane) compared with the untreated control (Fig. 3 A, 
fi  rst lane). To elucidate the composition of the transcription fac-
tor complex, we used antibodies against the p50 (Fig. 3 B, left) 
and p65 subunits (Fig. 3 B, right) of NF-κB. As shown in Fig. 
3 B (left), the lower and the upper NF-κB shifts contained the p50 
subunit. Therefore, the two bands were signifi  cantly reduced 
when an α-p50 antibody was included in the binding reaction 
and a new band, the p50 supershift, occurred. Only the upper 
NF-κB shift included the p65-subunit, as indicated by the addi-
tion of the α-p65 antibody, which provoked the reduction of the 
upper NF-κB shift, but did not alter the lower NF-κB shift (Fig. 
3 B, right). As expected, a new band was detectable (the p65 
supershift). Thus, we conclude that the lower NF-κB shift is 
formed by a p50 homodimer, whereas the upper NF-κB shift 
consists of a p50/p65 heterodimer.
To identify whether activation of NF-κB complexes is 
infl  uenced by PPARγ activation, we treated RAW 264.7 cells 
with the natural PPARγ agonist 15-deoxy-∆
12,14-prostaglandin 
J2 (15d-PGJ2; Kobayashi et al., 2005; Rogler, 2006). Taking into 
consideration that 15d-PGJ2 may also act PPARγ independently 
on NF-κB activation (Straus et al., 2000), we included the 
PPARγ antagonist GW9662 in this experiment (Leesnitzer 
et al., 2002). This allowed us to discover to what extent 15d-PGJ2 
affected PMA-mediated NF-κB activation PPARγ dependently. 
As depicted in Fig. 3 C, pretreatment of RAW 264.7 cells with 
10 μM 15d-PGJ2 for 1 h reduced the p50/p65 heterodimer for-
mation in response to PMA (Fig. 3 C, second lane) compared 
with PMA-treated controls (Fig. 3 C, fi  rst lane). Preincubation 
of the cells for 1 h with 10 μM GW9662 completely eliminated 
the infl  uence of 15d-PGJ2 on NF-κB activation (Fig. 3 C, right 
lane). To show that these results are not restricted to our cell line 
model, we performed a similar EMSA using nuclear extracts 
isolated from primary human macrophages. In primary cells, 
10 μM of the natural PPARγ agonist 15d-PGJ2 inhibits 100 nM 
PMA-mediated NF-κB activation (Fig. 3 D, middle lane), which 
is restored after 10 μM GW9662 pretreatment for 1 h (Fig. 3 D, 
right lane). However, in human macrophages, only one NF-κB 
shift in response to PMA, which is formed by a p50/p65 hetero-
dimer (unpublished data), is observed. From these results, we 
reasoned that PPARγ activation reduced the NF-κB DNA-   
binding ability in response to PMA by  50% compared with 
PMA-treated controls. To determine whether reduced NF-κB 
activation modulates expression of proinfl  ammatory cytokines, 
we fi  nally examined TNF-α expression of RAW 264.7 macro-
phages in response to PMA. TNF-α expression was determined 
Figure 2.  PPAR𝗄 agonist prestimulation inhibits PKC𝗂 depletion. RAW 
264.7 macrophages (A) and PPARγ1 AF2–overexpressing RAW 264.7 
cells (B) were prestimulated for 1 h with ciglitazone (1 or 10 μM), rosiglita-
zone (1 or 10 μM), or remained as controls, followed by the addition of 
100 nM PMA for 1 h. (C) RAW 264.7 macrophages were stimulated for 
1 h with 50 μg/ml CHX. Thereafter, 10 μM of rosiglitazone or ciglitazone 
were added for 1 h, followed by 100 nM PMA stimulation for 1 h. (D) Pri-
mary monocyte–derived macrophages were prestimulated for 1 h with 
10 μM ciglitazone, 10 μM rosiglitazone, or remained as controls. Afterward, 
100 nM PMA was added for 1 h. For all experiments, cells were harvested 
and lysed, and Western blot was performed as described in the Materials 
and methods. Experiments were performed at least three times, and repre-
sentative data are shown.JCB • VOLUME 176 • NUMBER 5 • 2007  684
by the cytometric bead array using a FACSCanto fl  owcytometer. 
As shown in Fig. 3 E, pretreatment of RAW 264.7 macro-
phages for 1 h with 10 μM rosiglitazone before addition of 
100 nM PMA for 6 h reduced PMA-mediated TNF-α expression 
to   70%. These results suggest that activated PPARγ1 
inhibits PKCα-dependent signaling in macrophages, thereby 
provoking, at least in part, an attenuated proinfl  ammatory gene 
expression profi  le in association with cellular desensitization.
PPAR𝗄1-dependent inhibition 
of PKC𝗂 translocation
Considering that activation of PKCα, followed by its translocation 
to the cell membrane, is a prerequisite for its depletion, we were 
interested to determine whether PPARγ blocks PKCα trans-
location. To follow PPARγ and PKCα distribution in RAW 264.7 
cells, we stained for PPARγ and PKCα in   paraformaldehyde-
fi  xed cells (Fig. 4). As shown in Fig. 4 A (third panel), PPARγ 
localizes in the cytosol and the nucleus in untreated cells, 
whereas PKCα is localized in the cytosol (Fig. 4 A, second 
panel). The nucleus is counterstained, using DAPI (Fig. 4 A, 
fi  rst panel), and an overlay is provided in Fig. 4 A (fourth panel). 
To prove specifi  city of the secondary antibodies used, which 
were labeled with either Alexa Fluor 488 or 546, we used these 
antibodies alone without a fi  rst antibody. In both cases, no signal 
is observed (unpublished data). Activation of the cells with 
100 nM PMA for 50 min provokes PKCα translocation (Fig. 4 B, 
second panel), whereas localization of PPARγ is not altered 
(Fig. 4 B, third panel). Pretreatment of RAW 264.7 macro-
phages with 10 μM of the synthetic PPARγ agonist rosiglitazone 
for 1 h prevents PKCα translocation in response to 100 nM 
PMA stimulation for 50 min (Fig. 4 C, second panel). Localization 
of PPARγ remains unaltered (Fig. 4 C, third panel). To prove a 
PPARγ-dependent effect, we used the PPARγ-specifi  c antago-
nist GW9662. Preincubation of the cells for 1 h with 10 μM 
GW9662, followed by rosiglitazone treatment (1 h, 10 μM), 
restores PKCα translocation after 100 nM PMA addition for 
50 min (Fig. 4 D, second panel). PPARγ localization was not af-
fected (Fig. 4 D, third panel). From these data, we conclude that 
activated cytosolic PPARγ in RAW 264.7 macrophages inhibits 
Figure 3.  PPAR𝗄1-dependent attenuation of PKC𝗂 translocation provokes 
a reduction of the proinﬂ  ammatory response in macrophages. (A) Activa-
tion of NF-κB in RAW 264.7 macrophages in response to PMA. RAW 
264.7 macrophages were stimulated for 3 h with 100 nM PMA or left un-
treated as control. Afterward, cells were harvested, nuclear extracts were 
isolated, and NF-κB EMSA was performed as described in the Materials 
and methods. (B) Supershift analysis of the active NF-κB complex was de-
scribed in the Materials and methods. Macrophages were stimulated with 
100 nM PMA for 3 h. For supershift analysis, a p50 antibody (left, second 
lane) or a p65 antibody (right, second lane) was included. NF-κB activa-
tion without antibody addition (left and right, ﬁ  rst lane) is shown. (C) 15d-
PGJ2 inhibited PMA-mediated NF-κB activation. RAW 264.7 cells were 
pretreated with 10 μM of the endogenous PPARγ ligand 15-dPGJ2 for 1 h, 
followed by the addition of 100 nM PMA for 3 h (middle lane). To ensure 
a PPARγ-dependent effect, one sample was prestimulated before 15d-PGJ2 
addition with 10 μM of the PPARγ antagonist GW9662 for 1 h (right 
lane). One sample remained PMA treated only as a control (left lane). Cells 
were harvested, nuclear protein extracts were isolated, and NF-κB EMSA 
was performed as described in Materials and methods. (D) PMA-mediated 
NF-κB activation is inhibited in human primary macrophages in response 
to 15d-PGJ2. Primary monocyte–derived macrophages were treated as de-
scribed in C. Cells were harvested and processed, and NF-κB EMSA was 
performed as described in Materials and methods. (E) Inhibition of PMA-
mediated PKCα activation by PPARγ reduced proinﬂ  ammatory  TNF-α 
expression. RAW 264.7 cells were treated for 1 h with 10 μM rosiglitazone 
or remained as controls. Afterward, cells were incubated with 100 nM 
PMA for 6 h, and TNF-α expression in the cell supernatant was analyzed 
using the CBA system. All experiments were performed at least three times. 
Data are the means ± the SD of the individual experiments (*, P < 0.05) 
or representative of three similar experiments.PPARγ1 INHIBITS PKCα TRANSLOCATION • VON KNETHEN ET AL. 685
PKCα translocation in response to 100 nM PMA. Based on the 
aforementioned Western blot results, RAW 264.7 cells express 
isoform 1, which is partially located in the cytosol.
To verify the impact of PPARγ1 activation on PKCα 
translocation, we used HEK293 cells. Cells were transiently 
transfected with a PPARγ1 wild-type–encoding vector, tagged 
with DsRed-monomer or a DsRed-monomer–tagged PPARγ1 
AF2 mutant–encoding vector in combination with a PKCα-
EGFP–encoding vector. The PPARγ1 AF2 mutant contains two 
amino acid exchanges (L468A/E471A), thus preventing ligand 
binding and concomitant PPARγ1 activation (Gurnell et al., 
2000). To follow PKCα translocation, 100 nM PMA was added 
to rosiglitazone-pretreated and control cells. Changes in PKCα 
localization were documented 1 h after rosiglitazone stimula-
tion and 50 min after 100 nM PMA addition. PMA provokes 
PKCα-EGFP translocation to the cell membrane in DsRed-
tagged PPARγ1 wild type, as well as DsRed-tagged PPARγ 
AF2 mutant–expressing cells, as expected (Fig. 5 A, second 
row, second panel vs. fourth row, second panel). Localization of 
PPARγ does not change (Fig. 5 A, fi  rst row, third panel vs. second 
row, third panel; and third row, third panel vs. fourth row, 
third panel). In cells transfected with the DsRed-tagged PPARγ1 
wild-type construct, rosiglitazone pretreatment inhibited PKCα-
EGFP translocation to the cell membrane in response to PMA 
(Fig. 5 B, second row, second panel), whereas in cells trans-
fected with the DsRed-tagged PPARγ AF2 mutant, rosiglitazone 
preincubation does not prevent PKCα-EGFP translocation (Fig. 
5 B, fourth row, second panel). However, PPARγ localization 
remains unaltered in all analyzed samples (Fig. 5, A and B, fi  rst 
through fourth row, third panel). As shown in Fig. 5 C, preincu-
bation of the cells with the PPARγ antagonist GW9662 (10 μM) 
for 1 h, completely abolished the PPARγ-dependent inhibition 
of PKCα translocation in response to PMA (bottom row, second 
panel). Inline pretreatment of the cells with the PPARα agonist 
WY14643 (10 μM) for 1 h did not inhibit PMA-mediated 
PKCα translocation (Fig. 5 D, bottom row, second panel), 
which further approved a PPARγ-dependent effect. In corrobo-
ration with Fig. 5 (A and B), PPARγ localization was unaffected 
in response to GW9662 or WY14643 and PMA treatment 
(Fig. 5, C and D, fi  rst and second row, third panel).
Based on these fi  ndings, we went on to analyze whether 
PPARγ1 inhibits PKCα translocation by a direct protein–
protein interaction.
PPAR𝗄1 directly binds to PKC𝗂
To elucidate whether PPARγ1 inhibits PKCα translocation by a 
direct PPARγ1–PKCα interaction, we performed a set of coimmuno-
precipitation experiments. Immunoprecipitation of PKCα from 
lysates of differentiated THP-1 cells, which had been stimulated 
for 1 h with rosiglitazone or left untreated, was conducted. As shown 
in Fig. 6 A, immunoprecipitation of PKCα resulted in coimmuno-
precipitation of PPARγ1 in THP-1 cells that had been challenged 
with a PPARγ agonist (Fig. 6 A, lane 2). In the fl  owthrough, 
PPARγ1 was only detected when agonist stimulation was omitted 
(Fig. 6 A, lane 1). After PPARγ1 activation, PPARγ1 was almost 
completely retarded in the immunoprecipitation column.
To verify a PPARγ1-dependent mechanism, we transfected 
COS-7 cells with PPARγ1 wild-type or AF2-encoding plasmids 
and a PKCα-EGFP expression plasmid. Immunoprecipitation was 
performed using μMacs anti-GFP beads. In cells transfected 
with the PPARγ1 AF2 mutant, little if any PPARγ1 coimmuno-
precipitated with PKCα-EGFP in response to 10 μM rosiglitazone 
(Fig. 6 B, lane 4). In cells transfected with the PPARγ1 wild-
type plasmid, rosiglitazone treatment allowed to coimmuno-
precipitate PPARγ1 with PKCα-EGFP  (Fig. 6 B, lane 2), pointing 
to the importance of agonist activation to promote PKCα binding.
To provide further evidence for a direct PPARγ1–PKCα 
interaction, we used the mammalian two-hybrid system. In 
COS-7 cells transiently transfected by electroporation with a 
combination of pCMV-AD-PPARγ1, pCMV-BD-PKCα, and 
the Gal4 reporter vector pFR-luc, addition of rosiglitazone or 
ciglitazone provoked induction of luciferase expression as 
determined by a luciferase assay. As shown in Fig. 7, addition of 
both PPARγ agonists induce luciferase expression roughly 
threefold compared with untreated controls. A PPARγ-dependent 
effect was verifi   ed because addition of the PPARα agonist 
Figure 4.  PKC𝗂 and PPAR𝗄 localization in 
RAW 264.7 macrophages. To follow PKCα and 
PPARγ localization in RAW 264.7 macro-
phages, cells were seeded on slides and 
treated (B) for 50 min with 100 nM PMA, (C) 
preincubated with 10 μM rosiglitazone for 1 h 
followed by 100 nM PMA addition for 50 min, 
or (D) pretreated with 10 μM GW9662 before 
cells were stimulated as described in C. After-
ward, cells were ﬁ  xed and stained for PKCα 
and PPARγ as described in the Materials and 
methods. Cell nuclei were counterstained with 
DAPI. DAPI staining is shown in the ﬁ  rst panel, 
PKCα staining in the second, PPARγ staining in 
the third, and an overlay to estimate cytosolic 
and nuclear region is provided in the fourth 
panel. All experiments were performed three 
times, and representative data are shown.JCB • VOLUME 176 • NUMBER 5 • 2007  686
WY14643 left basal luciferase activity unaltered. With this two-
hybrid model, direct binding of target (PPARγ1) to bait protein 
(PKCα) is required to induce luciferase expression. Therefore, 
our data suggest that PPARγ1 directly binds PKCα upon ago-
nist activation. This interaction inhibits PKCα translocation to 
the cell membrane, and thus, PKCα activation.
Identiﬁ  cation of PPAR𝗄1 domains involved 
in PKC𝗂 binding
To identify PPARγ1 domains that promote binding to PKCα, 
we fi  rst generated a set of point mutations, each substituting one 
aa in helix 4 of the ligand-binding domain (LBD), taking into 
consideration that this region is important in binding transcrip-
tional coactivators (Nolte et al., 1998; Westin et al., 1998), and 
therefore might be responsible for binding to PKCα as well. We 
generated six clones, with L309, N310, G312, V313, L316A, or 
K317 being individually substituted by an alanine (Fig. 8 A). In 
addition, we generated the construct PPARγ1 ∆aa309-319, with 
helix 4 (aa309-319) being completely removed (Fig. 8 A). To 
prove the functionality of these constructs, we fi  rst verifi  ed their 
expression by Western blotting. As a control, the DsRed-PPARγ1 
wild-type–encoding vector was included in the experiment. 
Figure 5.  PPAR𝗄1 inhibits PKC𝗂 translocation. 
HEK293 cells were cotransfected with DsRed-
PPARγ1 wild type/PKCα-EGFP (A and B [top 
two rows] and C and D) or DsRed-PPARγ1 
AF2/PKCα-EGFP (A and B, bottom two rows). 
To follow PKCα-EGFP translocation, 100 nM 
PMA was added to control cells (A, second 
and fourth row) or cells pretreated for 1 h with 
10  μM rosiglitazone (B, second and fourth 
row). To verify the role of PPARγ on PKCα-
EGFP translocation in DsRed-PPARγ1 wild 
type/PKCα-EGFP, cotransfected HEK293 cells 
were treated for 1 h with 10 μM of the PPARγ 
antagonist GW9662 before stimulation for 1 h 
with 10 μM rosiglitazone (C, top row) fol-
lowed by 50 min of 100 nM PMA addition 
(C, bottom row) or preincubated for 1 h with 
10 μM of the PPARα agonist WY14643 (D, top 
row) before activation with 100 nM PMA for 
50 min (D, bottom row). Cell nuclei were counter-
stained with DAPI. DAPI staining is shown in 
the ﬁ   rst panel, PKCα-EGFP in the second, 
DsRed-PPARγ in the third, and an overlay to es-
timate cytosolic and nuclear region is provided 
in the fourth panel. All experiments were per-
formed three times, and representative data 
are shown.PPARγ1 INHIBITS PKCα TRANSLOCATION • VON KNETHEN ET AL. 687
  Because of a single aa exchange, or the 12 aa deletion, the molec-
ular mass of proteins originating from the constructs remained 
unaltered compared with DsRed-PPARγ1 wild type when trans-
fected into HEK293 cells (unpublished data).
To fi nally analyze the impact of the various mutations and 
the deletion on PKCα translocation, HEK293 cells were transiently 
cotransfected with the mutated/deleted PPARγ1 constructs 
tagged with DsRed-monomer, in combination with a PKCα-
EGFP–encoding vector. PKCα localization was documented in 
cells that were untreated (Fig. 8, B and C, fi  rst rows), treated for 
50 min with PMA (Fig. 8, B and C, second rows), treated for 
1 h with rosiglitazone (Fig. 8, B and C, third rows), or preincu-
bated for 1 h with rosiglitazone, followed by the addition of 
PMA for 50 min (Fig. 8, B and C, fourth rows). In cells trans-
fected with one of the six constructs of the DsRed-tagged 
PPARγ1 mutations (L309A, N310A, and G312A [Fig. 8 B]; 
V313A, L316A, and K317A [Fig. 8 C]), PKCα-EGFP did 
not translocate to the cell membrane. A similar result was ob-
tained in cells transfected with DsRed-PPARγ1 ∆aa309-319 
(Fig. 8 C, right), showing no PMA-mediated PKCα-EGFP 
translocation in rosiglitazone-pretreated cells. From these data, 
we conclude that helix 4 of the LBD is not involved in PPARγ1 
binding to PKCα.
Based on these results, we decided to generate three 
PPARγ1 deletion constructs (DsRed-PPARγ1 aa∆32-198, DsRed-
PPARγ1 ∆aa32-250, and DsRed-PPARγ1 ∆aa51-406) with the 
belief that ligand binding is necessary for PPARγ1–PKCα 
interactions. As shown in Fig. 9 A, all deletions lack the 
DNA-binding domain (DBD) of PPARγ1. Furthermore, to 
characterize the role of the hinge domain in PKCα binding, it 
was eliminated to variable extents. In the DsRed-PPARγ1 
∆aa32-198 construct, the fi  rst 26 aa of the hinge domain were 
deleted, and in the DsRed-PPARγ1 ∆aa32-250 construct, 78 aa 
of the hinge domain were deleted. The hinge domain was com-
pletely removed in the DsRed-PPARγ1 ∆aa51-406 construct. In 
this construct, a part of the LBD/AF2 domain was deleted as well 
(aa288-406). All constructs lack a part of the AF1 domain.
Expression of the cloned constructs was verifi  ed by West-
ern blotting. As controls, the DsRed-PPARγ1 wild-type– and 
AF2 mutant–encoding vectors were included in the experiment. 
Estimated molecular mass of deletion construct proteins, trans-
fected into HEK293 cells, were verifi  ed using an anti–red fl  uo-
rescent protein antibody (Fig. 9 B). Taking into account that the 
DBD was removed, DNA binding and concomitant transactiva-
tion by corresponding PPARγ1 deletion constructs should be 
abolished. Therefore, we performed a set of reporter experi-
ments, cotransfecting DsRed-PPARγ deletion constructs in 
combination with a PPRE-reporter plasmid into HEK293 cells. 
As expected, adding 10 μM rosiglitazone for 6 h to cells trans-
fected with the PPARγ1 deletion constructs did not alter basal 
transactivation. In contrast, the DsRed PPARγ1 wild-type–
  encoding plasmid provoked a twofold induction of luciferase 
expression, whereas the DsRed PPARγ1 AF2 dominant-negative 
mutant blocked transactivation even below basal values, mediated 
by endogenous PPARγ in HEK293 cells (unpublished data).
To elucidate the role of these deletions on PKCα 
translocation, HEK293 cells were transiently cotransfected with 
the shortened DsRed-monomer–tagged PPARγ1 constructs in 
Figure 6.  PPAR𝗄1 directly interacts with PKC𝗂. (A) THP-1 cells were dif-
ferentiated for 24 h with 50 nM PMA. To allow new synthesis of PKCα, 
which is depleted in response to the differentation regime, cells were fur-
ther cultured for 48 h in normal medium. Afterward, cells were treated for 
1 h with 10 μM rosiglitazone or remained as controls. Cells were har-
vested and lysed, and PKCα was immunoprecipitated as described in Ma-
terials and methods. Eluates and ﬂ  owthroughs were separated by Western 
blotting and stained for PPARγ and PKCα as indicated. (B) COS-7 cells 
were transiently cotransfected with PPARγ1 wild type/PKCα-EGFP or 
PPARγ1 AF2/PKCα-EGFP. 24 h later, cells were treated for 1 h with 10 μM 
rosiglitazone or remained as controls. Cells were harvested and lysed, and 
PKCα-EGFP was immunoprecipitated as described in Materials and methods. 
Input controls, eluates, and ﬂ   owthroughs were separated by Western 
blotting and stained for PPARγ and PKCα as indicated. All experiments 
were performed at least three times, and representative data are shown.
Figure 7.  PPAR𝗄 directly binds to PKC𝗂. COS-7 cells were transiently trans-
fected with a combination of a target (PPARγ1), a bait (PKCα), and a reporter 
construct, as described in Materials and methods. Afterward, cells were 
treated with 10 μM ciglitazone, 10 μM rosiglitazone, 10 μM WY14643, or 
remained as controls. 6 h later, cells were harvested and lysed for a reporter 
analysis as described in Materials and methods.   Experiments were performed 
at least three times in duplicate. *, P < 0.05. Data are the means ± the SD.JCB • VOLUME 176 • NUMBER 5 • 2007  688
combination with a PKCα-EGFP–encoding vector. To follow 
PKCα translocation, 100 nM PMA was added to (1 h, 10 μM) 
rosiglitazone-pretreated cells. PKCα localization was docu-
mented in untreated cells (Fig. 9 C, fi  rst row), cells treated for 
50 min with PMA (Fig. 9 C, second row), for 1 h with rosiglita-
zone (Fig. 9 C, third row), or preincubated for 1 h with rosiglita-
zone, followed by the addition of PMA for 50 min  (Fig. 9 C, 
fourth row). In cells transfected with the DsRed-tagged PPARγ1 
∆aa32-198 construct, PKCα-EGFP did not translocate to the 
cell membrane. However, in cells expressing the DsRed-tagged 
PPARγ1  ∆aa32-250 or ∆aa51-406 construct, PKCα trans-
located to the cell membrane in response to 100 nM PMA.
From these data, we conclude that for PKCα, binding a 
part of the hinge domain of PPARγ1 is indispensable. To further 
narrow the involved region of PPARγ1, we fi  nally created the 
construct DsRed-PPARγ1 ∆aa206-224 (Fig. 10 A), containing 
a deletion of helix 1 (aa206-224) of PPARγ1, which is located 
in the hinge domain (aa173-288). Helix 1 has already been 
identifi  ed to mediate the protein–protein interaction of PPARγ 
with ERK5 (Akaike et al., 2004). Expression of the construct 
results as expected in protein, demonstrating a slightly reduced 
protein mass (Fig. 10 B, lane 2) because of the aa206-224 deletion 
compared with the DsRed-PPARγ1 wild type (Fig. 10 B, lane 1). 
We transiently cotransfected HEK cells with the PPARγ1 
∆aa206-224 construct tagged with DsRed-monomer in combi-
nation with a PKCα-EGFP–encoding vector. In cells expressing 
the DsRed-tagged PPARγ1  ∆aa206-224 (Fig. 10 C), PKCα 
translocated to the cell membrane in response to 100 nM PMA.
Figure 8.  Helix 4 of the LBD/AF2 domain 
does not mediate PPAR𝗄 binding to PKC𝗂. 
(A) Scheme of the PPARγ1 constructs. (B and C) 
HEK293 cells were cotransfected with DsRed-
PPARγ1 wild type/PKCα-EGFP (B, ﬁ  rst panel), 
DsRed-PPARγ1 L309A/PKCα-EGFP (B, second 
panel), DsRed-PPARγ1 N310A/PKCα-EGFP 
(B, third panel), DsRed-PPARγ1 G312A/PKCα-
EGFP (B, fourth panel), PPARγ1 V313A/
PKCα-EGFP (C, ﬁ  rst panel), PPARγ1 L316A/
PKCα-EGFP (C, second panel), PPARγ1 
K317A/PKCα-EGFP (C, third panel) or DsRed-
PPARγ1  ∆aa309-319/PKCα-EGFP (C, fourth 
panel). To follow PKCα-EGFP localization, 24 h 
after transfection, cells were treated for 50 min 
with 100 nM PMA (second row), for 1 h 
with 10 μM rosiglitazone (third row), pre-
treated for 1 h with 10 μM rosiglitazone fol-
lowed by the addition of 100 nM PMA for 
50 min (fourth row) or remained as controls 
(ﬁ  rst row). Experiments were performed three 
times, and representative data are shown.PPARγ1 INHIBITS PKCα TRANSLOCATION • VON KNETHEN ET AL. 689
We conclude that PPARγ1 binds to PKCα via the helix 1, 
which is located in the hinge domain of PPARγ1.
Discussion
Recently, we demonstrated that monocyte/macrophage desensi-
tization at least partially attenuates PKCα signaling (von 
Knethen et al., 2005; Johann et al., 2006). We provide evidence 
that PPARγ agonists block PKCα translocation to the cell mem-
brane and concomitant protein depletion, which normally oc-
curs after cell activation. In monocytic cell lines, PPARγ 
expression has been previously described (McIntyre et al., 2003; 
Musiek et al., 2005; von Knethen et al., 2005), and it was veri-
fi   ed using primary human monocyte–derived macrophages. 
These data corroborate the work of Tontonoz et al. (1998) and 
Chinetti et al. (1998), showing PPARγ expression in differenti-
ated macrophages. However, even if PPARγ  is expressed, 
PPARγ agonists are known to mediate PPARγ-dependent 
and -independent effects (Nosjean and Boutin, 2002). To this end, 
15d-PGJ2 has been described to directly modify H-ras, provoking 
a constitutively active enzyme (Oliva et al., 2003) or inhibiting 
I-κB kinase, and thus suppressing NF-κB signaling (Straus 
et al., 2000). Our approach, using cells expressing PPARγ1 
wild type or the PPARγ1 agonist-binding mutant AF2, substan-
tiates the need of PPARγ activation in our system. Only in cells 
expressing PPARγ1 wild type was translocation of PKCα 
blocked by PPARγ activation. The PPARγ1 AF2 mutant did not 
prevent PMA-mediated PKCα translocation. These data sup-
port the notion of a PPARγ-dependent mechanism.
PPARγ-mediated inhibition of classical PKCs has been 
previously described (Verrier et al., 2004). In their case, PKCβ 
translocation was blocked by PPARγ agonists via DGKα 
up-regulation. DGKα metabolizes DAG, which is an established 
activator of classical and novel PKC isoforms. Therefore, its 
induction/activation will remove the potential PKC activator, 
causing desensitization as seen in our experiments. However, in 
Figure 9.  Hinge domain mediates PPAR𝗄1 
binding to PKC𝗂. (A) Scheme of the PPARγ1 
constructs. (B) HEK293 cells were transiently 
transfected with one of the PPARγ1 constructs, 
as indicated. 24 h after transfection cells were 
lysed. Western blotting was performed, and 
blots were stained for DsRed. All experiments 
were performed at least three times, and 
representative data are shown. (C) HEK293 
cells were transfected with PKCα-EGFP only 
(ﬁ   rst panel) or cotransfected with DsRed-
PPARγ1 wild type/PKCα-EGFP (second panel), 
DsRed-PPARγ1  ∆32-198/PKCα-EGFP (third 
panel), DsRed-PPARγ1  ∆32-250/PKCα-EGFP 
(fourth panel), or DsRed-PPARγ1  ∆51-406/
PKCα-EGFP (ﬁ  fth panel). To follow PKCα-EGFP 
localization, 24 h after transfection, cells were 
treated for 50 min with 100 nM PMA (second 
row), treated for 1 h with 10 μM rosiglitazone 
(third row), pretreated for 1 h with 10 μM ros-
iglitazone followed by the addition of 100 nM 
PMA for 50 min (fourth row), or remained con-
trols (ﬁ   rst row). Experiments were performed 
three times, and representative data are shown.JCB • VOLUME 176 • NUMBER 5 • 2007  690
our experiments, a role of DGKα up-regulation must be ex-
cluded because the protein-synthesis inhibitor CHX did not 
restore PKCα translocation. In line with this, our PPARγ1 
∆aa32-198 construct, where the PPARγ1 DBD was removed, 
still inhibits PKCα translocation. Further support for our hypo-
thesis, suggesting a direct PPARγ1–PKCα interaction in pre-
venting PKCα translocation, came from previous studies 
(Johann et al., 2006). In this case, PPARγ was activated in re-
sponse to apoptotic cells, attenuating PKCα translocation and 
concomitant ROS production. In this study, the role of PPARγ 
was verifi  ed using a PPARγ d/n cell line. In these cells, pretreat-
ment with apoptotic cells left PMA-mediated PKCα transloca-
tion and subsequent ROS production unaltered. A premise for 
this assumption is that PPARγ is expressed at least partially in 
the cytosol. Generally, the nuclear hormone receptor PPARγ is 
described to be exclusively localized in the nucleus (Akiyama 
et al., 2002; Feige et al., 2005). In support of our hypothesis, 
suggesting cytoplasmatic localization as well, we noticed a mi-
nor amount of PPARγ1 to remain in the cytosol. This is based 
on results using DsRed-PPARγ1–transfected cells, as well as 
immunohistochemical detection of endogenous PPARγ1 lo-
cated in the cytosol of RAW 264.7 macrophages besides its ma-
jor nuclear localization. It should be noted that cytoplasmatic 
distribution of PPARγ is in line with the work of Abella et al. 
(2005). In their study, an approach similar to our experiments 
was used, with EGFP-tagged PPARγ used to characterize intra-
cellular distribution of PPARγ. Results indicated that PPARγ is 
not exclusively located in the nucleus. Furthermore, localiza-
tion of PPARγ in the cytoplasma in the promonocytic cell lines 
HL-60 and K-562 has been observed, especially in response to 
the PPARγ agonist troglitazone (Liu et al., 2005). This work 
was done using immunohistochemical detection of endogenous 
PPARγ. Therefore, side effects, such as unphysiological high 
expression or a modifi  ed protein behavior as a result of a tag or label 
(Feige et al., 2005), can be excluded. In addition, Burgermeister 
et al. (2006) recently provided evidence that PPARγ is ac-
tively exported from the nucleus into the cytosol in a MEK1-
dependent manner, further supporting our observed PPARγ 
localization pattern. Furthermore, Patel et al. (2005) described 
cytoplasmatic localization of a different PPAR isoform, PPARα, 
when coexpressed with CAP350, which is a putative centro-
some-associated protein of unknown function. Therefore, we 
propose that members of the PPAR family may localize in the 
cytoplasm, possibly after activation, when bound to cytoplasmic 
proteins such as PKCα. Immunoprecipitation of PKCα from 
lysates of differentiated THP-1 cells coimmunoprecipitated 
PPARγ. Remarkably, PPARγ1 coimmunoprecipitation was 
only seen once PPARγ1 became activated. The requirement of 
PPARγ1 activation was verifi  ed using an agonist-binding mu-
tant of PPARγ1, which did not block PKCα translocation in 
response to PMA stimulation. A direct PPARγ1–PKCα inter-
action was further supported by a mammalian two-hybrid sys-
tem with PPARγ1 as the target and PKCα as the bait construct, 
provoking luciferase reporter gene expression when target and 
bait proteins interact. To avoid autocrine activation of the re-
porter system, PPARγ has to be cloned as a target protein linked 
to the NF-κB transactivation domain, not allowing this hybrid 
protein to bind to the promoter of the reporter. However, DNA 
binding of PPARγ1 to PPREs, and concomitant scavenging the 
NF-κB-AD-PPARγ1 hybrid protein from the two-hybrid assay, 
cannot be excluded.
Based on the well-established role of helix 4 of the PPARγ 
LBD in mediating protein–protein interaction of PPARγ with 
coactivators, such as CBP and SRC-2, or repressors, such as the 
nuclear receptor corepressor and the silencing mediator for retinoic 
acid receptor and thyroid-hormone receptor (Nolte et al., 1998; 
Westin et al., 1998; Perissi et al., 1999; Perissi and Rosenfeld, 
2005), we fi  rst generated 6 PPARγ1 constructs in which only 
Figure 10.  Hinge helix 1 mediates PPAR𝗄1 binding 
to PKC𝗂.  (A) Scheme of the PPARγ1 construct. 
(B) HEK293 cells were transiently transfected with 
the DsRed-PPARγ1 wild type as control or the 
DsRed-PPARγ1  ∆aa206-224 construct as indi-
cated. 24 h after transfection, cells were lysed. 
Western blotting was performed, and blots were 
stained for DsRed. (C) HEK293 cells were cotrans-
fected with DsRed-PPARγ1  ∆aa206-224/PKCα-
EGFP. 24 h after transfection, cells were treated for 
1 h with 10 μM rosiglitazone. To follow PKCα-
EGFP translocation, 100 nM PMA was added to 
cells, and localization of PKCα-EGFP was exam-
ined 50 min thereafter. Experiments were performed 
three times and representative data are shown.PPARγ1 INHIBITS PKCα TRANSLOCATION • VON KNETHEN ET AL. 691
1 aa was exchanged and 1 construct in which helix 4 was com-
pletely removed. Unexpectedly, these constructs did not alter 
rosiglitazone-dependent inhibition of PKCα translocation.
Taking into account that PPARγ binding to other factors, 
such as adipocyte-type fatty acid–binding protein or extracellular 
signal-related kinase 5, which do not belong to the family of 
transcriptional coactivators, can be mediated by other PPARγ 
domains, such as A/B/C and D/E/F (Adida and Spener, 2006) or 
the hinge domain (domain D; Akaike et al., 2004), we created 
three PPARγ1 deletion constructs. All of them lack the entire 
DBD (domain C). In addition, different parts of the A/B and D 
domains have been removed, and one construct contained the 
C-terminal third of the E/F domains only. Based on our collec-
tive results, we provide evidence that a part of the hinge domain 
probably confers the PPARγ1–PKCα interaction, which is pre-
sent in the PPARγ1  ∆aa32-198 construct but absent in the 
∆aa32-250 construct, when PPARγ1 is activated by an agonist, 
thus requiring the LBD/AF2 domains. One known region of 
PPARγ1 located in aa198-250 is the hinge helix 1 (aa 206–224). 
Therefore, we cloned a PPARγ1 construct with helix 1deleted 
(DsRed- PPARγ1 ∆aa206-224). In cells transfected with this 
construct, PKCα translocated even after rosiglitazone pretreat-
ment in response to PMA. From these results, we conclude that 
PPARγ1 binds to PKCα via the hinge helix 1 domain, after 
PPARγ1 has been activated by a ligand.
The proposed mechanism of PPARγ1–PKCα binding 
proceeds fast. 1 h of prestimulation with PPARγ agonists is suf-
fi  cient to inhibit PKCα translocation in response to 100 nM 
PMA. However, PKCα translocation by 1 μM PMA was not 
blocked. These results support the assumption that the capacity 
of cytoplasmatic PPARγ to bind PKCα correlates with the 
strength of PKCα activation. Likely, very strong activation sig-
nals, such as 1 μM PMA, exceed the inhibitory impact of 
PPARγ. Thus, the role of PPARγ in blocking PKCα signaling 
might be only transient, allowing PKCα activation by a more 
stringent activator. This makes the mechanism more interesting 
for the development of new therapy strategies. Prolonged pe-
riods of PPARγ activation, which provoke transcriptional con-
trol to target members of the NADPH oxidase system, have 
already been described (p22
phox, p47
phox, and gp91
phox; Inoue 
et al., 2001; von Knethen and Brune, 2002; Hwang et al., 2005). 
Consequently, in these cells PPARγ contributes to an anti-
infl  ammatory phenotype by blocking NADPH oxidase-dependent 
ROS production.
An involvement of PPARγ in attenuating infl  ammatory 
reactions to improve the clinical picture of sepsis has previously 
been shown (for review see Zingarelli and Cook, 2005). In line 
with this, our results add to this data. In our system, PMA-
mediated NF-κB activation was inhibited in response to PPARγ 
agonist pretreatment to 50% in RAW 264.7 cells, as well as pri-
mary human macrophages. In accordance, PMA-induced TNF-α 
expression was PPARγ dependently reduced to 70%. It has 
been observed that PPARγ activation inhibits multiple organ 
failure in an animal model (Abdelrahman et al., 2005), although 
the underlying mechanism remains unclear. The option to adjust 
a pro- versus antiinfl  ammatory monocyte/macrophage pheno-
type will provide new possibilities for the development of 
therapies to control systemic infl  ammation. Our data add a new 
antiinfl  ammatory role for PPARγ based on the ability to scav-
enge PKCα in the cytosol, thus, blocking membrane transloca-
tion and downstream signaling.
Materials and methods
Monocyte isolation
We analyzed human cells from peripheral blood of healthy donors. For 
monocyte enrichment, we isolated PBMCs from donors using Ficoll-
Hypaque gradients (PAA Laboratories). Cells were left to adhere on culture 
dishes (Primaria 3072; Becton Dickinson) for 60 min at 37°C. Nonadherent 
cells were removed. Afterward, cells were differentiated to macrophages 
by culturing them in complete RPMI containing 10% AB-positive human 
serum. Flow cytometry conﬁ  rmed that the monocyte-like population was 
90–95% pure (CD14
+ vs. CD14
−).
Cell culture
We cultivated RAW 264.7 and THP-1 in RPMI 1640 (PAA Laboratories). 
HEK293 and COS-7 cells were cultured in DME high glucose (PAA Labora-
tories). Both media were supplemented with 100 U/ml penicillin (PAA 
Laboratories), 100 μg/ml streptomycin (PAA Laboratories), and 10% heat-
inactivated fetal calf serum (PAA Laboratories). Ciglitazone (Biomol), 
rosiglitazone (Biomol), WY14643 (Biomol), and CHX (Sigma-Aldrich) 
were dissolved in DMSO. Appropriate vehicle controls were performed.
Immunoﬂ  uorescence staining
To determine intracellular PPARγ localization, we seeded RAW 264.7 mac-
rophages directly on a slide. After 24 h, cells were treated as indicated 
and ﬁ  xed on the slides by 1-h incubation in 4% paraformaldehyde at 4°C. 
Thereafter, cells were permeabilized in PBS containing 0.2% Triton X-100 
for 15 min. After a washing step in PBS, cells were incubated for 2 h with 
a 1:250 dilution of a rabbit α-PPARγ antibody (Calbiochem) at 4°C. After 
three 5-min washing steps with PBS, cells were incubated with a secondary 
goat α-rabbit antibody (1:250) labeled with Alexa Fluor 546 (Invitrogen) 
for 2 h at 4°C. Cells were incubated for 2 h with a 1:250 dilution of a 
mouse α-PKCα antibody (BD Biosciences) at 4°C. After three 5-min wash-
ing steps with PBS, cells were incubated with a secondary goat α-mouse 
antibody (1:250) labeled with Alexa Fluor 488 (Invitrogen) for 2 h at 4°C. 
Again, cells were washed three times with PBS and counterstained with 
DAPI (1 μg/ml in PBS for 15 min). After a ﬁ  nal 5-min washing step in PBS, 
cells were covered with Vectashield mounting medium (Linaris) and a 
coverslip. PPARγ and PKCα localization were determined using an AxioScope 
ﬂ   uorescence microscope with the ApoTome upgrade (Carl Zeiss Micro-
Imaging, Inc.; lens 63×/0.6 NA; ocular 10×) at room temperature, docu-
mented by a charge-coupled device camera (Carl Zeiss MicroImaging, 
Inc.) and AxioVision Software (Carl Zeiss MicroImaging, Inc.).
Vector construction, transient transfection, ﬂ  uorescence microscopy, 
and reporter analysis
To examine cellular PPARγ localization, we subcloned human PPARγ1 into 
the DsRed-monomer–encoding vector pDsRed-Monomer-C1 (CLONTECH 
Laboratories, Inc.) using the infusion ligation kit (CLONTECH Laboratories, 
Inc.). To allow integration of the PPARγ1 fragment, the vector was cut 
within the multicloning site (MCS) by BamHI and XhoI. To insert PPARγ1 
(provided by V.K.K. Chatterjee, University of Cambridge, Cambridge, UK), 
we used the pcDNA3-PPARγ1 wild-type and AF2 vectors for PPARγ1 am-
pliﬁ  cation by PCR, using the following sequences based on the infusion 
ligation requirements (changed nucleotides are underlined): wild type, 
5′-G  G  A  C  T  C  A  G  A  T  C  T  C  G  A  A  T  G  G  T  T  G  A  C  A  C  A  G  A  G  A  T  C   GCATTCTG-3′ and 
3′-A  G  G  A  C  G  T  C  C  T  C  T  A  G  A  T  G  T  T  C  C  T  G  A  A  C  A  T  G  C  T  A  G  G  T  G  G  C  C  T   AGA T-5′; 
AF2 mutant, 5′-G  G  A  C  T  C  A  G  A  T  C  T  C  G  A  A  T  G  G  T  T  G  A  C  A  C  A  G  A  G  A  T  CGCAT-
TCTG-3′ and 3′-GA  G  A  C  G  T  C  C  G  C  T  A  G  A  T  G  T  T  C  C  T  G  A  A  C  A  T  G  C  T  A  G  G  T  G  G-
C  C  T   AGAT-5′. Annealing temperatures were 62°C for the ﬁ  rst cycle and 
72°C for the later ones and calculated using the Oligo software (MBI). Infu-
sion reaction of the cleaved vector with the ampliﬁ  ed PPARγ1 wild-type or 
AF2 fragment was performed according to the distributor’s instructions.
Site-directed mutagenesis to generate single aa exchanges 
(L309A, N310A, G312A, V313A, L316A, K317A) and deletion of he-
lix 1 (aa206-224) or 4 (aa309-319) of PPARγ1 were performed using 
the QuikChange XLII kit (Stratagene). The following primers were used 
(changed nucleotides are underlined): L309A, 5′-C  C  T  G  G  T  T  T  T  G  T  A  A  A  T  C-
T  T  G  A  C  G  CG  A  A  C  G  A  C  C  A  A  G  T  A  A  C  T  C  T  C  C  T  C  -3′ and 5′-G  A  G  G  A  G  A  G  T-JCB • VOLUME 176 • NUMBER 5 • 2007  692
T  A  C  T  T  G  G  T  C  G  T  T  C  G  C  G  T  C  A  A  G  A  T  T  T  A  C  T  T  T  T  C  C  A  G  G  -3′; N310A, 5′-CC 
TG  G  T  T  T  T  G  T  A  A  A  T  C  T  T  G  A  C  T  T  G  G  C  G  G  A  C  C  A  A  G  T  A  A  C  T  C  T  C  C  T  C  -3′ and 
5′-GAGGAGAG T T  A  C  T  T  G  G  T  C  C  G  C  C  A  A  G  T  C  A  A  G  A  T  T  T  A  C  T  T  T  T  C  C  A  G  G  -3′; 
G312A, 5′-G  T  A  A  A  T  C  T  T  G   A  C  T  T  G  A  A  C  G  A  C  G  C  G  G  T  A  A  C  T  C  T  C  C  T  C  A  A  A-
T  A  T  G  G  -3′ and 5′-C  C  A  T  A  T  T  T  G  A  G  G  A  G  A  G  T   T  A  C  C  G  C  G  T  C  G  T  T  C  A  A  G  T  C- 
A  A  G  A  T  T  T  A  C  -3′; V313A, 5′-G  T  A  A  A  T  C  T  T  G  A  C  T  T  G  A  A  C  G  A   C C  A  A  G  C  G  A  C-
T  C  T  C  C  T  C  A  A  A  T  A  T  G  G  -3′ and 5′-C  C  A  T  A  T  T  T  G  A  G  G  A  G  A  G  T  C  G  C  T  T  G  G  T  C  G-   
T  T  C  A  A  G  T  C  A  A  G  A  T  T  T  A  C  -3′; L316A, 5′-C  T  T  G  A  A  C  G  A  C  C  A  A  G  T  A  A  C  T  C  T  C-
G  C  G  A  A  A  T   A  T  G  G  A  G  T  C  C  A  C  G  A  G  -3′ and 5′-C  T  C  G  T  G  G  A  C  T  C  C  A  T  A  T  T  T-
C  G  C  G  A  G  A  G  T  T  A  C  T  T  G  G  T  C  G   TTCAAG-3′; K317A, 5′-C  T  T  G  A  A  C  G  A  C  C-
A  A  G  T  A  A  C  T  C  T  C  C  T  C  G  C  G  T  A  T  G  G  A  G  T  C  C  A  C   GAG-3′ and 5′-C  T  C  G  T  G  G-
A  C  T  C  C  A  T  A  C  G  C  G  A  G  G  A  G  A  G  T  T  A  C  T  T  G  G  T  C  G  T  T  C  A  A  G  -3′; ∆aa309-319, 
5′-C  C  T  G  G  T  T  T  T  G  T A  A  A T  C  T  T  G  A  C  C  C  G  C  T  G  A  C  C  A  A  A  G  C  A  A  A  G  -3′  and 5′-CTTT
GC  T  T  T  G  G  T  C  A  G  C  G  G  G  T  C  A  A  G  A  T  T  T  A  C  A  A  A  A  C  C  A  G  G  -3′. The pcDNA3-
PPARγ1 wild-type vector was used as a template. An initial denaturation 
step was performed at 95°C for 1 min, followed by 18 cycles at 95°C for 
50 s, annealing at 60°C for 50 s, and extension at 68°C for 7 min. A ﬁ  nal 
extension phase was performed at 68°C for 7 min.
DsRed-PPARγ1 ∆aa32-198 was constructed by deleting the EcoRV 
fragment in the DsRed-PPARγ1 wild-type vector. DsRed-PPARγ1 ∆aa32-250 
was constructed by deleting the EcoRV–EcoRI fragment in the DsRed-
PPARγ1 wild-type vector, blunting the sticky EcoRI end before religating the 
remaining plasmid. Finally, DsRed-PPARγ1 ∆aa51-406 was constructed by 
deleting the XmnI fragment in the DsRed-PPARγ1 wild-type vector. Restric-
tion enzymes were obtained from New England Biolabs. The Klenow frag-
ment and T4 ligase were provided by Fermentas. All manipulations did not 
alter the open reading frame of PPARγ1.
Correct orientation and sequence of the generated vectors was 
  veriﬁ  ed by restriction analyses and/or sequencing. The PKCα-EGFP signal-
ing sample (pPKCα-EGFP) used was obtained from CLONTECH Labora-
tories, Inc.
To follow PKCα translocation and PPARγ distribution, HEK293 cells 
were seeded directly onto a slide, and then transiently transfected by 
CaPO4-precipitation with combinations of pDsRed-Monomer-C1 PPARγ1 
wild type/pPKCα-EGFP, pDsRed-Monomer-C1 PPARγ1 AF2/pPKCα-EGFP, 
or the generated deletion and mutation constructs together with pPKCα-
EGFP. 24 h after transfection, cells were used for experiments. Cells were 
treated as indicated. Afterward, cells were ﬁ  xed on the slides by 1-h incu-
bation in 4% paraformaldehyde at 4°C. Cells were washed three times 
with PBS and counterstained with DAPI (1 μg/ml in PBS for 15 min). After 
a ﬁ  nal 5-min washing step in PBS, cells were covered with Vectashield 
mounting medium and a coverslip. Translocation of PKCα-EGFP and DsRed-
PPARγ1 wild type/AF2 distribution was analyzed using an AxioScope ﬂ  uo-
rescence microscope with the ApoTome upgrade (lens 63×/0.6 NA; 
ocular 10×) at room temperature, documented by a charge-coupled de-
vice camera and the AxioVision Software.
For reporter analysis, HEK293 cells were transiently transfected by 
CaPO4-precipitation with pDsRed-Monomer-C1 PPARγ1 wild-type, -AF2, 
∆aa32-198, ∆32-250, ∆51-406 constructs, or the empty DsRed vector 
in combination with the PPRE-containing p(AOX)3-TK-luc reporter plasmid. 
Transfection efﬁ  ciency was normalized by cotransfecting a pRL-TK control 
vector encoding for Renilla reniformis luciferase. Transfections were 
  performed in duplicate, and each experiment was repeated at least 
three times.
Coimmunoprecipitation
After THP-1, cells were differentiated for 24 h with 50 nM PMA, PMA was 
removed, and cells were incubated for an additional 48 h in complete 
medium. Afterward, cells were stimulated for 1 h with 10 μM rosiglitazone 
or remained as controls. Eventually, cells were harvested and lysed in lysis 
buffer (50 mM Tris, 5 mM EDTA, 150 mM NaCl, 0.5% Nonidet-40, and 
1 mM PMSF, pH 8.0). To assure cell lysis, cells were sheared 10 times with 
a 16-gauge needle, followed by a brief 10-s sonication (Soniﬁ  er; Branson; 
duty cycle 100%, output control 60%). Cell debris was removed by centrif-
ugation (10,000 g for 5 min), and 1 mg of protein was used for immuno-
precipitation. Sample volume was adjusted with lysis buffer to 1 ml. 2 μg 
anti-PKCα antibody (BD Biosciences) was added and incubated at 4°C 
overnight. Thereafter, 50 μl μMACS protein A microbeads (Miltenyi Biotech) 
were added and incubated for 6 h. Lysate was applied onto an equili-
brated μ column, which was already placed in the magnetic ﬁ  eld of a 
μMACS separator. The ﬂ  owthrough was collected and saved for further 
analysis. The column was rinsed 4 times with 200 μl wash buffer (150 mM 
NaCl, 1% Igepal CA-630, 0.5% sodium deoxycholate, 0.1% SDS, and 
50 mM Tris HCl, pH 8.0), followed by 2 washes with low ionic buffer (20 mM 
TrisHCl, pH 7.5). Afterward, the column was removed from the magnetic 
ﬁ  eld and the remaining proteins were eluted using 50 μl of lysis buffer.
COS-7 cells were transiently transfected by electroporation (450 
V/300  μF; Equibio Easyjet T Prima; Peqlab) with a combination of 
pcDNA3 PPARγ1 wild-type or pcDNA3-PPARγ1 AF2 and pPKCα-EGFP. 
Immunoprecipitation was performed as described in the previous paragraph 
using μMACS anti–GFP-microbeads (Miltenyi Biotec)
Mammalian two-hybrid assay
To use PPARγ1 and PKCα in the mammalian two-hybrid system (Strata-
gene), PPARγ1 was cloned into the BamHI–HindIII site of the pCMV-AD 
MCS, and PKCα was cloned into the BamHI–HindIII site of the pCMV-BD 
MCS. PPARγ was ampliﬁ  ed from the pcDNA3-PPARγ1 wild-type vector and 
PKCα from the vector pPKCα-EGFP. The following primers were used: 
pCMV-BD-PPARγ1, 5′-GCCGGAA T T  G  G  G  A  T  C  C  A  T  G  G  T  T  G  A  C  A  C  A  G  A  G  A-
T  G  C  C  A  T  T  C  T  G  -3′ and 5′-A  C  G  C  G  G  C  C  G  C  A  A  G  C   T  C  T  A  G  T  A  C  A  A  G  T  C  C  T  T-
G  T  A  G  A  T  C  T  C  C  T  G  C  A  G  G  -3′; pCMV-AD-PKCα, 5′-CAGCGGCC A  A  G  G  A  T-
  C  C  A  T  G  G  C  T  G  A  C  G  T  T  T  T  C  C  C  G  G  G  -3′ and 5′-A  C  G  C  G  G  C  C  G  C  A  A  G  C-
T  T  C  A  T  A   C  T  G  C  A  C  T  C  T  G  T  A  A  G  A  T  G  G  G  G  T  G  C  -3′. Annealing temperatures 
were 62°C for the ﬁ  rst cycle and 72°C for the later ones, and were cal-
culated using the Oligo software (MBI). Infusion reaction of the BamHI–
HindIII–cleaved vectors with the ampliﬁ  ed PPARγ1 wild-type- or PKCα-
fragment was performed according to the distributor’s instructions. Correct 
orientation and sequence of the generated vectors was veriﬁ  ed by restric-
tion analyses and sequencing. COS-7 cells were transiently transfected by 
electroporation using a combination of the two constructed vectors, as well 
as the pFR-luciferase reporter vector (Stratagene). Afterward, cells were 
incubated for 24 h, and then stimulated for 6 h with 10 μM ciglitazone, 
10 μM rosiglitazone, or 10 μM WY14643, or they remained as controls. 
Thereafter, cells were lysed and assayed for ﬁ  reﬂ  y luciferase activity by a 
luciferase assay (Promega).
Western blot analysis
Cell lysis was achieved with lysis buffer (50 mM Tris, 5 mM EDTA, 150 mM 
NaCl, 0.5% Nonidet-40, and 1 mM PMSF, pH 8.0) and 20-s sonication 
(Soniﬁ  er; duty cycle 100%, output control 60%). Whole-cell lysates were 
cleared by centrifugation (10,000 g for 5 min), and protein concentration 
was determined with the Lowry method. 80 μg of protein was resolved on 
10% polyacrylamide gels and blotted onto nitrocellulose sheets, basically 
following standard methodology. Equal loading and correct protein transfer 
to nitrocellulose was routinely quantitated by Ponceau S staining. Filters 
were incubated with the anti-PKCα antibody (1:500; BD Biosciences), anti-
PPARγ antibody (1:500; Santa Cruz Biotechnology, Inc.), anti-RFP antibody 
(1:1,000; MBL), or anti-actin antibody (1:2,000; GE Healthcare) overnight 
at 4°C. Horseradish peroxidase–conjugated polyclonal antibodies (1:5,000; 
GE Healthcare) were used for enhanced chemiluminescence detection.
Quantiﬁ  cation of TNF-𝗂 expression
Supernatants from RAW 264.7 macrophages treated as indicated were 
harvested after the indicated times. Content of TNF-α was quantiﬁ  ed using 
the BD Cytometric Bead Array TNF-α Flex Set (BD Biosciences) according 
to the supplier’s instructions using a FACSCanto ﬂ  owcytometer. Interpreta-
tion of the results was performed with the FCAP Array software (Soft Flow, 
Inc./BD Biosciences).
EMSA
Nuclear extracts were prepared as previously described (von Knethen and 
Brune, 2001). An established EMSA method, with slight modiﬁ  cations, 
was used (Camandola et al., 1996). Nuclear protein (20 μg) was in-
cubated for 30 min at room temperature with 2 μg poly(dI-dC) from GE 
Healthcare, 2 μl buffer D (20 mM Hepes/KOH, 20% glycerol, 100 mM 
KCl, 0.5 mM EDTA, 0.25% Nonidet P-40, 2 mM DTT, and 0.5 mM PMSF, 
pH 7.9), 4 μl buffer F (20% Ficoll-400, 100 mM Hepes/KOH, 300 mM 
KCl, 10 mM DTT, and 0.5 mM PMSF, pH 7.9), and 250 fmol 5′-IRD700–
labeled oligonucleotide (Metabion) in a ﬁ  nal volume of 20 μl. Speciﬁ  c 
p65 and p50 supershift antibodies (2 μg; Santa Cruz Biotechnology, Hei-
delberg, Germany) were added as indicated. DNA–protein complexes 
were resolved at 80 V for 1 h in a native 6% polyacrylamide gel, and visu-
alized with the Odyssey infrared imaging system (LI-COR). Oligonucleo-
tides with the consensus NF-κB site (bold letters) were used (Peng et al., 
1995): 5′-GCCAGTTGA G  G  G  G  A  C  T  T  T  C  C  C  A  G  G  C  -3′; 3′-C  G  G  T  C  A  A  C  T  C  C-
C  C  T  G  A  A  A  G   GGTCCG-5′.
Statistical analysis
Each experiment was performed at least three times. Statistical analysis 
was performed using the paired t test. We considered P values ≤ 0.05 as 
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